Insider Transactions in Q2 2024 at Bio Xcel Therapeutics, Inc. (BTAI)
Insider Transaction List (Q2 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 17
2024
|
Vimal Mehta CEO and President |
SELL
Open market or private sale
|
Direct |
2,134
-4.3%
|
$2,134
$1.28 P/Share
|
|
Jun 17
2024
|
Vincent O'Neill Officer |
SELL
Open market or private sale
|
Direct |
155
-4.21%
|
$155
$1.28 P/Share
|
|
Jun 17
2024
|
Javier Rodriguez Officer |
SELL
Open market or private sale
|
Direct |
361
-4.12%
|
$361
$1.26 P/Share
|
|
Jun 17
2024
|
Richard I Steinhart Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
372
-6.36%
|
$372
$1.26 P/Share
|
|
Jun 17
2024
|
Matthew T. Wiley Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
244
-6.52%
|
$244
$1.26 P/Share
|
|
Jun 17
2024
|
Frank Yocca Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
372
-2.69%
|
$372
$1.28 P/Share
|
|
Jun 15
2024
|
Vimal Mehta CEO and President |
BUY
Exercise of conversion of derivative security
|
Direct |
3,500
+6.58%
|
-
|
|
Jun 15
2024
|
Javier Rodriguez Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
562
+6.03%
|
-
|
|
Jun 15
2024
|
Richard I Steinhart Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
562
+8.77%
|
-
|
|
Jun 15
2024
|
Matthew T. Wiley Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
750
+16.7%
|
-
|
|
Jun 15
2024
|
Frank Yocca Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
562
+3.9%
|
-
|
|
Jun 14
2024
|
Vimal Mehta CEO and President |
BUY
Exercise of conversion of derivative security
|
Direct |
2,609
+5.35%
|
-
|
|
Jun 14
2024
|
Vincent O'Neill Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
521
+12.4%
|
-
|
|
Jun 14
2024
|
Javier Rodriguez Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
521
+5.98%
|
-
|
|
Jun 14
2024
|
Richard I Steinhart Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
521
+8.97%
|
-
|
|
Jun 14
2024
|
Frank Yocca Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
521
+3.77%
|
-
|
|
Jun 05
2024
|
Vimal Mehta CEO and President |
SELL
Open market or private sale
|
Indirect |
409,136
-50.81%
|
$409,136
$1.58 P/Share
|
|
Jun 04
2024
|
Vimal Mehta CEO and President |
SELL
Open market or private sale
|
Indirect |
1,018,358
-19.57%
|
$1,018,358
$1.63 P/Share
|
|
Apr 04
2024
|
Frank Yocca Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,067
-7.72%
|
$2,134
$2.63 P/Share
|
|
Apr 04
2024
|
Javier Rodriguez Officer |
SELL
Open market or private sale
|
Direct |
1,012
-11.65%
|
$2,024
$2.64 P/Share
|
|
Apr 04
2024
|
Matthew T. Wiley Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
1,008
-25.2%
|
$2,016
$2.64 P/Share
|
|
Apr 04
2024
|
Richard I Steinhart Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,069
-18.32%
|
$2,138
$2.63 P/Share
|
|
Apr 04
2024
|
Vimal Mehta CEO and President |
SELL
Open market or private sale
|
Direct |
5,268
-5.47%
|
$10,536
$2.62 P/Share
|
|
Apr 04
2024
|
Vincent O'Neill Officer |
SELL
Open market or private sale
|
Direct |
165
-2.96%
|
$330
$2.62 P/Share
|